Phytoestrogens/Flavonoids Reverse Breast Cancer Resistance Protein/ABCG2-Mediated Multidrug Resistance

Breast cancer resistance protein (BCRP), also called ABCG2, confers resistance to anticancer agents such as 7-ethyl-10-hydroxycamptothecin (SN-38), mitoxantrone, and topotecan. We found previously that sulfated estrogens are physiologic substrates of BCRP. Flavonoids with weak estrogenic activities are called phytoestrogens. In this study, we show that phytoestrogens/flavonoids, such as genistein, naringenin, acacetin, and kaempferol, potentiated the cytotoxicity of SN-38 and mitoxantrone in BCRP-transduced K562 (K562/BCRP) cells. Some glycosylated flavonoids, such as naringenin-7-glucoside, also effectively inhibited BCRP. These flavonoids showed marginal effect on the drug sensitivity of K562 cells. Genistein and naringenin reversed neither P-glycoprotein-mediated vincristine resistance nor multidrug resistance-related protein 1-mediated VP-16 resistance. Genistein and naringenin increased cellular accumulation of topotecan in K562/BCRP cells. K562/BCRP cells also accumulated less [3H]genistein than K562 cells. [3H]genistein transport in the basal-to-apical direction was greater in BCRP-transduced LLC-PK1 (LLC/BCRP) cells, which express exogenous BCRP in the apical membrane, than in parental cells. Fumitremorgin C abolished the increased transport of [3H]genistein in LLC/BCRP cells compared with parental cells. TLC analysis revealed that genistein was transported in its native form but not in its metabolized form. These results suggest that genistein is among the natural substrates of BCRP and competitively inhibits BCRP-mediated drug efflux. The results have two important clinical implications: (a) flavonoids and glycosylated flavonoids may be useful in overcoming BCRP-mediated drug resistance in tumor cells; and (b) coadministration of flavonoids with BCRP-substrate antitumor agents may alter the pharmacokinetics and consequently increase the toxicity of specific antitumor agents in cancer patients.

[1]  T. Tsuruo,et al.  Dominant‐negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S‐S dependent homodimerization , 2002, International journal of cancer.

[2]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Goffeau,et al.  Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters , 2002, Cellular and Molecular Life Sciences CMLS.

[4]  R. Newbold,et al.  Pharmacokinetic analysis in serum of genistein administered subcutaneously to neonatal mice. , 2002, Cancer letters.

[5]  T. Tsuruo,et al.  Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. , 2003, Molecular cancer therapeutics.

[6]  L. Doyle,et al.  Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. , 2001, Biochemical and biophysical research communications.

[7]  R. Walgren,et al.  Efflux of dietary flavonoid quercetin 4'-beta-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. , 2000, The Journal of pharmacology and experimental therapeutics.

[8]  T. Tsuruo,et al.  Efficient protection of cells from the genotoxicity of nitrosoureas by the retrovirus-mediated transfer of human O6-methylguanine-DNA methyltransferase using bicistronic vectors with human multidrug resistance gene 1. , 1998, Mutation research.

[9]  H. W. Scheeren,et al.  Beta-glucuronidase-mediated drug release. , 2002, Current pharmaceutical design.

[10]  Takashi Tsuruo,et al.  Breast cancer resistance protein exports sulfated estrogens but not free estrogens. , 2003, Molecular pharmacology.

[11]  P. Murphy,et al.  Glucuronides are the main isoflavone metabolites in women. , 2003, The Journal of nutrition.

[12]  Shuzhong Zhang,et al.  Effects of the Flavonoids Biochanin A, Morin, Phloretin, and Silymarin on P-Glycoprotein-Mediated Transport , 2003, Journal of Pharmacology and Experimental Therapeutics.

[13]  R Hori,et al.  Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. , 1992, The Journal of biological chemistry.

[14]  T. Litman,et al.  Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. , 1999, Cancer research.

[15]  J. Lankelma,et al.  Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. , 1994, Biochemical pharmacology.

[16]  I. Pastan,et al.  Genetic analysis of the multidrug transporter. , 1995, Annual review of genetics.

[17]  K. Setchell,et al.  Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. , 2001, The Journal of nutrition.

[18]  P. Waterman.  Plant Flavonoids in Biology and Medicine, Biochemical, Pharmacological and Structure-Activity Relationships : Edited by V. Cody, E. Middleton and J. B. Harborne. Alan R. Liss, New York, 1986. 592 pp + xxi. $76.00. , 1986 .

[19]  T. Litman,et al.  Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. , 1999, Cancer letters.

[20]  Xing-Tai Han,et al.  Effects of altitude, ambient temperature and solar radiation on fasting heat production in yellow cattle (Bos taurus) , 2003, British Journal of Nutrition.

[21]  K. Ueda,et al.  Anti‐cancer drugs and glutathione stimulate vanadate‐induced trapping of nucleotide in multidrug resistance‐associated protein (MRP) , 1997, FEBS letters.

[22]  T. Tsuruo,et al.  Estrone and 17β‐Estradiol Reverse Breast Cancer Resistance Protein‐mediated Multidrug Resistance , 2002, Japanese journal of cancer research : Gann.

[23]  A. F. Castro,et al.  Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein. , 1997, Biochemical pharmacology.

[24]  Vincenzo,et al.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. , 1998, Cancer research.

[25]  J. Schellens,et al.  Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. , 1999, Cancer research.

[26]  C. Vergely,et al.  In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. , 1993, Cancer research.

[27]  J. Corton,et al.  Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor β. , 1998, Endocrinology.

[28]  C. Rice-Evans,et al.  Interactions of the flavonoid naringenin in the gastrointestinal tract and the influence of glycosylation. , 1999, Biochemical and biophysical research communications.

[29]  L. Doyle,et al.  Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. , 2000, Cancer research.

[30]  J. Katzenellenbogen,et al.  Estrogen inhibition of cystic fibrosis transmembrane conductance regulator-mediated chloride secretion. , 2000, The Journal of pharmacology and experimental therapeutics.

[31]  J. Harborne,et al.  Nature, distribution and function of plant flavonoids. , 1986, Progress in clinical and biological research.

[32]  J. Schellens,et al.  Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.